Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02112526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02112526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
Lead sponsor
Acerta Pharma BV
Phase
Phase 1
Overall status
Completed
Start date
August 7, 2014
Completion date
October 4, 2024
Enrollment
21 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

activated b-cell diffuse large b-cell lymphoma (abc dlbcl)